Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Pharmacovigilance01:19

Pharmacovigilance

830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex differences in the global burden of autism spectrum disorders: An analysis based on GBD 2021 data.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences·2026
Same author

Enabling real-world evidence for medication safety in pregnancy: Determinants of research participation and linked EHR data use.

International journal of medical informatics·2026
Same author

Denture use is associated with a higher risk of cholelithiasis: a prospective cohort study.

BMC oral health·2026
Same author

The global burden of early-onset cancer in women, 1990-2021: findings from the GBD 2021 with focus on China.

Journal of the National Cancer Center·2026
Same author

Epidemiological Characteristics, Target Distribution, and Clinical Value of Targeted Anticancer Drugs Approved in China: A Cross-Sectional Study.

Clinical pharmacology and therapeutics·2026
Same author

Exposure to air pollution and risk of gastrointestinal diseases: a systematic review and meta-analysis of epidemiological evidence.

Epidemiologic reviews·2026

Related Experiment Video

Updated: Jun 28, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs.

Yafang Huang1, Jinqiu Yuan2

  • 1School of General Practice and Continuing Education, Capital Medical University, Beijing, China.

Expert Review of Clinical Pharmacology
|April 18, 2024
PubMed
Summary

Single-arm trials (SATs) for anticancer drugs face scrutiny due to limited evidence. This review highlights endpoint adjudication as key to improving data reliability and patient outcomes in cancer drug trials.

Keywords:
Oncological clinical trialanticancer activityendpoint adjudicationsafety outcomesingle-arm trialssurrogate endpoint

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.5K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.4K

Related Experiment Videos

Last Updated: Jun 28, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.5K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.4K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Drug Development

Background:

  • Single-arm trials (SATs) and surrogate endpoints have been primary evidence for accelerated anticancer drug approval for over 30 years.
  • Concerns about the quality of clinical evidence from SATs, particularly in oncology, are rising due to the lack of control and overall survival endpoints.
  • SATs may not provide robust evidence compared to randomized controlled trials.

Purpose of the Study:

  • To systematically review endpoint adjudication in surrogate and safety outcome assessments for anticancer drug trials.
  • To analyze the advantages and disadvantages of different adjudicator types and summarize their roles.
  • To propose strategies for enhancing data reliability and transparency in pivotal cancer drug trials.

Main Methods:

  • Systematic discussion of endpoint adjudication characteristics in surrogate and safety outcome assessments.
  • Analysis of adjudicator types, their roles, advantages, and disadvantages.
  • Review of existing literature on clinical trial evidence quality in oncology.

Main Results:

  • Endpoint adjudication is crucial for ensuring data quality, reliability, and transparency in surrogate outcome measurement.
  • Adjudication effectively reduces potential bias and variance introduced by investigators during medical record analysis.
  • A comprehensive understanding of adjudicator roles is essential for robust clinical trial outcomes.

Conclusions:

  • Improving data reliability and transparency in pivotal anticancer drug trials is essential.
  • Endpoint adjudication strategies can enhance the quality of clinical investigations.
  • Ultimately, these improvements aim to lead to better patient outcomes in cancer treatment.